Science
Andrea Necchi: A Combined Analysis of PURE01 and SURE02
Andrea Necchi / LinkedIn

Andrea Necchi: A Combined Analysis of PURE01 and SURE02

Andrea Necchi, Associate Professor at Università Vita-Salute San Raffaele, shared on X:

“Tumor mutational burden predicts the outcome of patients with muscle-invasive bladder cancer undergoing immune-checkpoint inhibitor-based neoadjuvant therapy – a combined analysis of PURE01 and SURE02.”

Title: Tumor mutational burden predicts the outcome of patients with muscle-invasive bladder cancer undergoing immune-checkpoint inhibitor-based neoadjuvant therapy

Authors: Chiara Mercinelli, Giuseppe Basile, Giovanni L. Pastorino, Antonio Cigliola, Brigida A. Maiorano, Valentina Tateo, Michela Piacentini, Debora Serafin, Gualtiero Guandalini, Roberta Lacava, Gaia Latini, Maurizio Colecchia, Alberto Briganti, Marco Moschini, Francesco Montorsi, Dean Pavlick, Jeffrey S. Ross, Andrea Necchi.

Read the article

You can also read: ‘BOND-003 Phase 3: Cretostimogene Shows 75% Complete Response Rate in BCG-Unresponsive NMIBC‘

BOND-003

Alberto Briganti Andrea Necchi Antonio Cigliola bladder cancer Brigida A. Maiorano Chiara Mercinelli Dean Pavlick Debora Serafin Francesco Montorsi Gaia Latini Giovanni L. Pastorino Giuseppe Basile GU Oncology Gualtiero Guandalini Jeffrey S. Ross Marco Moschini Maurizio Colecchia Michela Piacentini PURE01 Roberta Lacava SURE02 Università Vita-Salute San Raffaele Valentina Tateo